Water
( DrugBank: Water / KEGG DRUG: Water )
21 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 4 |
| 5 | 進行性核上性麻痺 | 1 |
| 6 | パーキンソン病 | 14 |
| 13 | 多発性硬化症／視神経脊髄炎 | 3 |
| 17 | 多系統萎縮症 | 2 |
| 22 | もやもや病 | 1 |
| 35 | 天疱瘡 | 1 |
| 46 | 悪性関節リウマチ | 8 |
| 53 | シェーグレン症候群 | 2 |
| 57 | 特発性拡張型心筋症 | 1 |
| 63 | 免疫性血小板減少症 | 1 |
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 65 | 原発性免疫不全症候群 | 2 |
| 67 | 多発性嚢胞腎 | 8 |
| 78 | 下垂体前葉機能低下症 | 0 |
| 84 | サルコイドーシス | 0 |
| 96 | クローン病 | 3 |
| 97 | 潰瘍性大腸炎 | 14 |
| 206 | 脆弱Ｘ症候群 | 1 |
| 226 | 間質性膀胱炎（ハンナ型） | 3 |
| 278 | 巨大リンパ管奇形（頚部顔面病変） | 1 |
| 299 | 嚢胞性線維症 | 12 |
2. 筋萎縮性側索硬化症
臨床試験数 : 786 / 薬物数 : 550 - (DrugBank : 182) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 232
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
5. 進行性核上性麻痺
臨床試験数 : 93 / 薬物数 : 97 - (DrugBank : 33) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 111
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
6. パーキンソン病
臨床試験数 : 2,586 / 薬物数 : 1,871 - (DrugBank : 354) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 205
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,685 / 薬物数 : 1,932 - (DrugBank : 355) / 標的遺伝子数 : 263 - 標的パスウェイ数 : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
17. 多系統萎縮症
臨床試験数 : 142 / 薬物数 : 142 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 110
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
22. もやもや病
臨床試験数 : 23 / 薬物数 : 29 - (DrugBank : 21) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 50
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
35. 天疱瘡
臨床試験数 : 120 / 薬物数 : 109 - (DrugBank : 40) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 167
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
46. 悪性関節リウマチ
臨床試験数 : 4,543 / 薬物数 : 2,251 - (DrugBank : 390) / 標的遺伝子数 : 198 - 標的パスウェイ数 : 232
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
53. シェーグレン症候群
臨床試験数 : 368 / 薬物数 : 277 - (DrugBank : 94) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 186
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
57. 特発性拡張型心筋症
臨床試験数 : 11 / 薬物数 : 17 - (DrugBank : 10) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
63. 免疫性血小板減少症
臨床試験数 : 575 / 薬物数 : 261 - (DrugBank : 64) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
65. 原発性免疫不全症候群
臨床試験数 : 798 / 薬物数 : 585 - (DrugBank : 118) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 216
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
67. 多発性嚢胞腎
臨床試験数 : 233 / 薬物数 : 188 - (DrugBank : 54) / 標的遺伝子数 : 60 - 標的パスウェイ数 : 165
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
78. 下垂体前葉機能低下症
臨床試験数 : 34 / 薬物数 : 44 - (DrugBank : 11) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 19
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
84. サルコイドーシス
臨床試験数 : 175 / 薬物数 : 189 - (DrugBank : 80) / 標的遺伝子数 : 74 - 標的パスウェイ数 : 177
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
96. クローン病
臨床試験数 : 2,737 / 薬物数 : 1,197 - (DrugBank : 240) / 標的遺伝子数 : 182 - 標的パスウェイ数 : 221
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
97. 潰瘍性大腸炎
臨床試験数 : 3,305 / 薬物数 : 1,646 - (DrugBank : 318) / 標的遺伝子数 : 165 - 標的パスウェイ数 : 220
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
206. 脆弱Ｘ症候群
臨床試験数 : 118 / 薬物数 : 75 - (DrugBank : 30) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 83
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
226. 間質性膀胱炎（ハンナ型）
臨床試験数 : 163 / 薬物数 : 158 - (DrugBank : 58) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
278. 巨大リンパ管奇形（頚部顔面病変）
臨床試験数 : 32 / 薬物数 : 32 - (DrugBank : 12) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
299. 嚢胞性線維症
臨床試験数 : 1,826 / 薬物数 : 1,271 - (DrugBank : 246) / 標的遺伝子数 : 118 - 標的パスウェイ数 : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|